AI Article Synopsis
- The study aimed to analyze the prevalence and characteristics of noninfectious scleritis within a large eye-care network over three years.
- Out of 1103 patients, most were around 44 years old, with 85% experiencing unilateral disease, primarily diffuse anterior and nodular scleritis.
- The findings suggest various treatment approaches, with topical corticosteroids being the most common initial therapy, and the study also emphasizes improvements in electronic medical records for better data collection.
Article Abstract
Purpose: To report the pattern of noninfectious scleritis across a tertiary eye-care network.
Methods: A three-year retrospective review of patients diagnosed with noninfectious scleritis was performed. Data were retrieved using diagnostic terms assigned to scleritis through the in-house eyeSmart-electronic medical record system.
Results: 1103 patients, with a mean age of 44.33 ± 14.38 years and a median follow-up of 199.5 days (range 32-685) were enrolled. Unilateral disease was noted in 85%. Diffuse anterior scleritis (n = 542, 42.51%) and nodular scleritis (n = 482, 38.12%) were the commonest subtypes. Systemic immune disease association was present in 65 (5.89%). Treatment at onset was topical corticosteroids (n = 372, 36.54%) followed by oral non-steroidal anti-inflammatory drugs (n = 351, 34.45%), oral corticosteroids in 184 (19.04%), and immunomodulators in 32 patients (3.54%).
Conclusions: This study depicts the pattern of various noninfectious scleritis in a large cohort of patients. The present study helped to further customize the electronic medical records to minimize several data capture limitations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2021.1942497 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Janus kinase inhibitors and their use in non-infectious orbital inflammatory disorders: new treatment possibilities? A case series.
Orbit
December 2024
Faculty of Medicine, Univerza v Ljubljani, Ljubljana, Slovenia.
We present a patient with isolated autoimmune anterior scleritis and a patient with nonspecific orbital inflammation (NSOI). Both patients were treated with systemic corticosteroids during multiple recurrences, with the addition of various disease-modifying antirheumatic drugs (DMARDs), including biologics, in the case of scleritis, resulting in complications and local adverse events. Both patients were subsequently effectively managed using Janus kinase inhibitors (JAK-i), specifically baricitinib and tofacitinib without relapses of inflammation during the follow-up of more than one year.
View Article and Find Full Text PDFOcular Adverse Events Following Coronavirus Disease 2019 Infection: A Self-controlled Case Series Study from the Entire Korean Population.
Ophthalmol Sci
October 2024
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Purpose: This study aimed to assess the risk of ocular adverse events, including retinal artery occlusion (RAO), retinal vein occlusion (RVO), noninfectious uveitis (NIU), noninfectious scleritis (NIS), optic neuritis (ON), ischemic optic neuropathy (ION), and ocular motor cranial nerve palsy (OMCNP), after coronavirus disease 2019 (COVID-19) infection.
Design: Population-based self-controlled case series (SCCS).
Participants: The study included patients from the entire Korean population of 52 million who experienced incident RAO, RVO, anterior NIU, nonanterior NIU, NIS, ON, ION, or OMCNP between January 1, 2021, and October 29, 2022.
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.
J Ophthalmic Inflamm Infect
October 2024
Department of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Background: Repository corticotropin injection (RCI) has been suggested to exert immunomodulatory and anti-inflammatory effects in ocular inflammation. The index retrospective study aimed to evaluate the efficacy and tolerability of subcutaneous RCI in patients with active scleritis or uveitis.
Main Body: Medical records of patients who were diagnosed with different types of active scleritis or uveitis and received RCI for more than six months at a tertiary eye center were reviewed.
Corrigendum: Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.
Front Med (Lausanne)
September 2024
Azienda Ospedaliero-Universitaria Senese [European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy.
Article Synopsis
- The article discusses corrections to research findings initially published.
- It emphasizes the importance of accuracy in scientific communication.
- This correction aims to ensure that readers are aware of any significant changes to the original data and conclusions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!